: Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion and can lead to multi-organ failure and death depending on its severity. Inadequate cardiac contractility or cardiac power secondary to acute myocardial infarction remains the most frequent cause of cardiogenic shock, although its contribution has declined over the past two decades, compared with other causes. Despite some advances in cardiogenic shock management, this clinical syndrome is still burdened by an extremely high mortality. Its management is based on immediate stabilization of haemodynamic parameters so that further treatment, including mechanical circulatory support and transfer to specialized tertiary care centres, can be accomplished. With these aims, medical therapy, consisting mainly of inotropic drugs and vasopressors, still has a major role. The purpose of this article is to review current evidence on the use of these medications in patients with cardiogenic shock and discuss specific clinical settings with indications to their use.

Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion and can lead to multi-organ failure and death depending on its severity. Inadequate cardiac contractility or cardiac power secondary to acute myocardial infarction remains the most frequent cause of cardiogenic shock, although its contribution has declined over the past two decades, compared with other causes. Despite some advances in cardiogenic shock management, this clinical syndrome is still burdened by an extremely high mortality. Its management is based on immediate stabilization of haemodynamic parameters so that further treatment, including mechanical circulatory support and transfer to specialized tertiary care centres, can be accomplished. With these aims, medical therapy, consisting mainly of inotropic drugs and vasopressors, still has a major role. The purpose of this article is to review current evidence on the use of these medications in patients with cardiogenic shock and discuss specific clinical settings with indications to their use.

Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors / Riccardi, Mauro; Pagnesi, Matteo; Chioncel, Ovidiu; Mebazaa, Alexandre; Cotter, Gad; Gustafsson, Finn; Tomasoni, Daniela; Latronico, Nicola; Adamo, Marianna; Metra, Marco. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1879-0844. - 26:2(2024), pp. 411-431. [10.1002/ejhf.3162]

Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors

Pagnesi, Matteo;Metra, Marco
2024-01-01

Abstract

Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion and can lead to multi-organ failure and death depending on its severity. Inadequate cardiac contractility or cardiac power secondary to acute myocardial infarction remains the most frequent cause of cardiogenic shock, although its contribution has declined over the past two decades, compared with other causes. Despite some advances in cardiogenic shock management, this clinical syndrome is still burdened by an extremely high mortality. Its management is based on immediate stabilization of haemodynamic parameters so that further treatment, including mechanical circulatory support and transfer to specialized tertiary care centres, can be accomplished. With these aims, medical therapy, consisting mainly of inotropic drugs and vasopressors, still has a major role. The purpose of this article is to review current evidence on the use of these medications in patients with cardiogenic shock and discuss specific clinical settings with indications to their use.
2024
Inglese
John Wiley and Sons Ltd
26
2
411
431
Goal 3: Good health and well-being
: Cardiogenic shock is a primary cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion and can lead to multi-organ failure and death depending on its severity. Inadequate cardiac contractility or cardiac power secondary to acute myocardial infarction remains the most frequent cause of cardiogenic shock, although its contribution has declined over the past two decades, compared with other causes. Despite some advances in cardiogenic shock management, this clinical syndrome is still burdened by an extremely high mortality. Its management is based on immediate stabilization of haemodynamic parameters so that further treatment, including mechanical circulatory support and transfer to specialized tertiary care centres, can be accomplished. With these aims, medical therapy, consisting mainly of inotropic drugs and vasopressors, still has a major role. The purpose of this article is to review current evidence on the use of these medications in patients with cardiogenic shock and discuss specific clinical settings with indications to their use.
Cardiogenic shock; Inotropes; Mechanical circulatory support; Vasopressors;
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors / Riccardi, Mauro; Pagnesi, Matteo; Chioncel, Ovidiu; Mebazaa, Alexandre; Cotter, Gad; Gustafsson, Finn; Tomasoni, Daniela; Latronico, Nicola; Adamo, Marianna; Metra, Marco. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1879-0844. - 26:2(2024), pp. 411-431. [10.1002/ejhf.3162]
none
10
info:eu-repo/semantics/article
262
Riccardi, Mauro; Pagnesi, Matteo; Chioncel, Ovidiu; Mebazaa, Alexandre; Cotter, Gad; Gustafsson, Finn; Tomasoni, Daniela; Latronico, Nicola; Adamo, Ma...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/193113
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 38
social impact